Latest news about encapsia

Challenges and Opportunities in Clinical Data Management

Written by Cmed
21 Mar 2019

A recent survey on the challenges and opportunities in clinical data management by Pharma Intelligence reveals the most pressing issues today include the absence of real-time access to clinical trial data and that 90% of the effort involved in aggregating, cleaning and transforming data is manual. Moreover, over 80% of the respondents considered that incomplete and inconsistent data represents the top issue for regulatory compliance. Lastly, perhaps one of the most important findings was that eSource data is the future - finding ways to clean and manage new forms of data will be the next step in the progress of clinical trials.

The survey was conducted on 155 qualified respondents from biotechs, large pharma companies and CROs, representing a significant voice of the market.

These findings came as no surprise as we see some of these same challenges facing the industry. The current patchwork of often quite dated clinical data systems and the use of separate tools, with inadequate interoperability usually leads to data lag, data errors, process inefficiencies, and regulatory challenges. As well as this, poor management and insight into trial progress and a lack of timely decision making are always a concern.

However, leveraging today’s technologies now offers an opportunity to address many of the principal trial process issues, with significant improvements in time, cost, and the quality of data collected.

That’s why at Cmed we created Encapsia, a powerful clinical data suite that delivers a complete solution to gather and manage data in clinical trials and give true, live insights on trial progress to inform and enhance management decisions.

Encapsia allows data to be captured flexibly, for example by mobile direct data capture (eSource), multi-media and web EDC. Data can be viewed live in visual insights and can provide real time analytics of both clinical metrics and trial performance.

Observations and issues can be highlighted, shared with study stakeholders, actioned, tracked and automatically compiled into clear auditable formats. The Encapsia suite is fully compliant with all relevant regulatory standards. The suite has also been designed to easily integrate with existing EDC platforms allowing customers to benefit from selected enhancements without having to displace all incumbent solutions.

We built Encapsia for the future of clinical trials. And we’d love to show you more.

For a no obligation chat on how encapsia can help you overcome current trial challenges contact:

Last 3 posts

Question: Your webinar presentation earlier this week was quite provocative. Could you tell us a bit more about your background? TCC: I started writing software and building computers from scratch from a very early age. My father and I ran an educational software company when I was a teenager, and then I went on to read Engineering and Computer Science at Oxford, capping this with a DPhil in AI before co-founding Cmed Technology - a lifetime writing, designing and creating enterprise platforms with a specialism and passion for the clinical trial space.
Cmed Technology announced today the encapsia Home Visit app is now available to capture and manage clinical trial data from patients at home or in the community. The app works seamlessly with all the other encapsia apps, including web EDC (Entry app) and direct data capture (esource app) to provide tremendous flexibility in the choice of data capture methods both before and during a study. This helps maintain patient participation and clinical data flow which is particularly compelling to minimize disruption during the COVID-19 pandemic as well as in the new landscape for clinical trials that is expected to follow.
The global COVID-19 crisis has fundamentally impacted the way we live our lives as well as the operation of the entire drug development community. During the early stages of the pandemic the Cmed leadership team has implemented a number of measures to ensure the safety of our employees, clients and partners, as well as ensuring the continued delivery of our CRO services and our encapsia clinical data system. Our goal has been to minimise the impact of COVID-19 on our business, our clients, investigator sites and patients.